ID_events | cancer | TypeID | ImmuneCell | P | R | CorrelationPlot |
ENSG00000189164.13,ZNF527 | ACC | EAG | Monocytes | 1.0893e-02 | -0.4820 |  |
chr19:37390080-37390330:+ | BRCA | EER | Macrophages_M1 | 4.7934e-02 | 0.1817 |  |
chr19:37391306-37392700:+ | BRCA | EER | T_cells_CD8 | 1.3596e-02 | 0.1339 |  |
ENSG00000189164.13,ZNF527 | CESC | EAG | Dendritic_cells_activated | 1.3698e-02 | 0.3610 |  |
chr19:37391306-37392700:+ | GBM | EER | B_cells_memory | 2.2291e-02 | 0.2085 |  |
ENSG00000189164.13,ZNF527 | KICH | EAG | Mast_cells_activated | 8.7262e-03 | 0.5698 |  |
ENSG00000189164.13,ZNF527 | KIRC | EAG | T_cells_gamma_delta | 2.9439e-03 | 0.3283 |  |
chr19:37391306-37392700:+ | KIRP | EER | Mast_cells_activated | 3.6691e-03 | 0.3854 |  |
ENSG00000189164.13,ZNF527 | KIRP | EAG | Mast_cells_activated | 2.9658e-03 | 0.3867 |  |
chr19:37391306-37392700:+ | LUSC | EER | Dendritic_cells_activated | 1.5056e-02 | 0.4547 |  |
ENSG00000189164.13,ZNF527 | LUSC | EAG | T_cells_gamma_delta | 1.3142e-03 | 0.4596 |  |
chr19:37390080-37390330:+ | OV | EER | Mast_cells_resting | 7.4769e-03 | 0.3979 |  |
chr19:37391306-37392700:+ | OV | EER | B_cells_memory | 1.7775e-02 | -0.3103 |  |
ENSG00000189164.13,ZNF527 | PRAD | EAG | T_cells_regulatory_(Tregs) | 1.2133e-02 | -0.1685 | .ENSG00000189164.13,ZNF527.png) |
ENSG00000189164.13,ZNF527 | SARC | EAG | T_cells_CD4_naive | 4.5753e-04 | 0.3600 |  |
ENSG00000189164.13,ZNF527 | SKCM | EAG | Plasma_cells | 4.8489e-03 | 0.4718 |  |
chr19:37390080-37390330:+ | STAD | EER | Macrophages_M1 | 4.7085e-02 | 0.3332 |  |
chr19:37391306-37392700:+ | STAD | EER | Macrophages_M0 | 3.9317e-02 | -0.3500 |  |
ENSG00000189164.13,ZNF527 | STAD | EAG | Macrophages_M1 | 2.0225e-02 | 0.2920 |  |
chr19:37391306-37392700:+ | TGCT | EER | B_cells_memory | 3.4286e-02 | 0.3443 |  |
ENSG00000189164.13,ZNF527 | TGCT | EAG | B_cells_memory | 3.2746e-03 | 0.4079 |  |
ENSG00000189164.13,ZNF527 | THCA | EAG | NK_cells_activated | 1.0211e-03 | -0.1881 |  |
ENSG00000189164.13,ZNF527 | THYM | EAG | Plasma_cells | 4.9767e-03 | 0.3496 |  |
chr19:37391306-37392700:+ | UCEC | EER | Dendritic_cells_activated | 3.9793e-02 | 0.2861 |  |
ENSG00000189164.13,ZNF527 | UCEC | EAG | Dendritic_cells_activated | 3.1636e-02 | 0.2956 |  |
ID_events | cancer | HallmarkType | Type | P | R | CorrelationPlot |
ENSG00000189164.13,ZNF527 | ACC | GSVA_HALLMARK_MTORC1_SIGNALING | EAG | 4.7448e-03 | 0.5269 |  |
chr19:37390080-37390330:+ | BRCA | GSVA_HALLMARK_MITOTIC_SPINDLE | EER | 3.7085e-03 | -0.2641 |  |
ENSG00000189164.13,ZNF527 | CESC | GSVA_HALLMARK_GLYCOLYSIS | EAG | 1.5678e-02 | 0.3544 |  |
ENSG00000189164.13,ZNF527 | ESCA | GSVA_HALLMARK_MYC_TARGETS_V2 | EAG | 6.5453e-03 | -0.5615 |  |
ENSG00000189164.13,ZNF527 | GBM | GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY | EAG | 1.5720e-02 | 0.2123 |  |
chr19:37391306-37392700:+ | GBM | GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY | EER | 3.9867e-02 | 0.1879 |  |
ENSG00000189164.13,ZNF527 | KIRP | GSVA_HALLMARK_DNA_REPAIR | EAG | 2.8898e-02 | 0.2896 |  |
chr19:37391306-37392700:+ | KIRP | GSVA_HALLMARK_DNA_REPAIR | EER | 2.8767e-02 | 0.2950 |  |
ENSG00000189164.13,ZNF527 | LGG | GSVA_HALLMARK_KRAS_SIGNALING_UP | EAG | 5.8977e-03 | 0.1636 |  |
ENSG00000189164.13,ZNF527 | LIHC | GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY | EAG | 8.6145e-03 | 0.4953 |  |
chr19:37391306-37392700:+ | LIHC | GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY | EER | 1.0891e-02 | 0.5434 |  |
chr19:37391306-37392700:+ | LUAD | GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY | EER | 3.1640e-02 | 0.3074 |  |
ENSG00000189164.13,ZNF527 | LUAD | GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY | EAG | 6.7907e-03 | 0.3459 |  |
chr19:37391306-37392700:+ | LUSC | GSVA_HALLMARK_MYOGENESIS | EER | 3.9216e-02 | -0.3918 |  |
chr19:37391306-37392700:+ | OV | GSVA_HALLMARK_KRAS_SIGNALING_UP | EER | 1.1378e-04 | 0.4851 |  |
chr19:37390080-37390330:+ | OV | GSVA_HALLMARK_KRAS_SIGNALING_UP | EER | 2.6663e-02 | -0.3341 |  |
chr19:37391306-37392700:+ | PCPG | GSVA_HALLMARK_HYPOXIA | EER | 2.6029e-02 | -0.2260 |  |
ENSG00000189164.13,ZNF527 | PCPG | GSVA_HALLMARK_HYPOXIA | EAG | 2.2814e-02 | -0.2298 |  |
ENSG00000189164.13,ZNF527 | SARC | GSVA_HALLMARK_KRAS_SIGNALING_DN | EAG | 5.3751e-03 | 0.2895 |  |
ENSG00000189164.13,ZNF527 | SKCM | GSVA_HALLMARK_PROTEIN_SECRETION | EAG | 1.5154e-02 | -0.4132 |  |
ENSG00000189164.13,ZNF527 | STAD | GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE | EAG | 3.7160e-02 | 0.2632 |  |
ENSG00000189164.13,ZNF527 | TGCT | GSVA_HALLMARK_TGF_BETA_SIGNALING | EAG | 2.1708e-02 | -0.3240 |  |
chr19:37391306-37392700:+ | TGCT | GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE | EER | 4.0916e-02 | 0.3332 |  |
ENSG00000189164.13,ZNF527 | THCA | GSVA_HALLMARK_COAGULATION | EAG | 1.0645e-03 | 0.1874 |  |
ENSG00000189164.13,ZNF527 | THYM | GSVA_HALLMARK_ANDROGEN_RESPONSE | EAG | 4.5604e-04 | -0.4287 |  |
chr19:37391306-37392700:+ | UCEC | GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING | EER | 4.4950e-02 | 0.2793 |  |
ENSG00000189164.13,ZNF527 | UCEC | GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING | EAG | 3.4404e-02 | 0.2912 |  |
ID_events | cancer | Drug | Type | P | R | CorrelationPlot |
ENSG00000189164.13,ZNF527 | ACC | IPA.3 | EAG | 4.5167e-03 | -0.5294 |  |
chr19:37390080-37390330:+ | BRCA | Bryostatin.1 | EER | 3.9822e-02 | -0.1887 |  |
ENSG00000189164.13,ZNF527 | BRCA | Elesclomol | EAG | 1.6242e-02 | -0.1216 |  |
ENSG00000189164.13,ZNF527 | CESC | ATRA | EAG | 4.5757e-03 | 0.4108 |  |
ENSG00000189164.13,ZNF527 | ESCA | AZD.2281 | EAG | 2.0509e-02 | -0.4904 |  |
chr19:37391306-37392700:+ | GBM | Cytarabine | EER | 1.0116e-02 | 0.2340 |  |
ENSG00000189164.13,ZNF527 | GBM | GDC0941 | EAG | 3.7666e-03 | 0.2534 |  |
ENSG00000189164.13,ZNF527 | KICH | CGP.082996 | EAG | 7.0379e-03 | 0.5825 |  |
ENSG00000189164.13,ZNF527 | KIRC | Erlotinib | EAG | 4.3800e-04 | -0.3840 |  |
ENSG00000189164.13,ZNF527 | KIRP | Dasatinib | EAG | 3.6470e-02 | -0.2827 |  |
chr19:37391306-37392700:+ | KIRP | Dasatinib | EER | 4.4331e-02 | -0.2774 |  |
ENSG00000189164.13,ZNF527 | LGG | GDC0941 | EAG | 1.1513e-02 | 0.1503 |  |
ENSG00000189164.13,ZNF527 | LIHC | AZD7762 | EAG | 3.0067e-05 | -0.7129 |  |
chr19:37391306-37392700:+ | LIHC | Bosutinib | EER | 3.1644e-04 | 0.7094 |  |
chr19:37391306-37392700:+ | LUSC | Camptothecin | EER | 1.0671e-02 | -0.4748 |  |
ENSG00000189164.13,ZNF527 | LUSC | A.770041 | EAG | 5.4027e-04 | -0.4904 |  |
ENSG00000189164.13,ZNF527 | OV | Doxorubicin | EAG | 3.9057e-02 | 0.2180 |  |
chr19:37391306-37392700:+ | OV | Doxorubicin | EER | 4.2995e-04 | 0.4474 |  |
chr19:37390080-37390330:+ | OV | Erlotinib | EER | 1.2368e-03 | -0.4714 |  |
chr19:37391306-37392700:+ | PCPG | Imatinib | EER | 8.0137e-03 | 0.2678 |  |
ENSG00000189164.13,ZNF527 | PCPG | Imatinib | EAG | 1.1670e-02 | 0.2538 |  |
ENSG00000189164.13,ZNF527 | PRAD | AG.014699 | EAG | 3.4296e-02 | -0.1425 |  |
ENSG00000189164.13,ZNF527 | SARC | Elesclomol | EAG | 3.2796e-03 | -0.3051 |  |
ENSG00000189164.13,ZNF527 | SKCM | GSK269962A | EAG | 1.0081e-03 | -0.5389 |  |
chr19:37391306-37392700:+ | STAD | Dasatinib | EER | 3.8106e-03 | -0.4898 |  |
ENSG00000189164.13,ZNF527 | STAD | AZD.0530 | EAG | 4.6239e-02 | -0.2628 |  |
ENSG00000189164.13,ZNF527 | TGCT | GDC.0449 | EAG | 1.6471e-02 | -0.3377 |  |
chr19:37391306-37392700:+ | TGCT | BMS.754807 | EER | 1.7948e-02 | 0.3820 |  |
ENSG00000189164.13,ZNF527 | THCA | CI.1040 | EAG | 1.0766e-04 | -0.2210 |  |
ENSG00000189164.13,ZNF527 | THYM | AZD6244 | EAG | 3.3343e-05 | -0.4976 |  |
chr19:37391306-37392700:+ | UCEC | IPA.3 | EER | 9.7602e-03 | 0.3552 |  |
ENSG00000189164.13,ZNF527 | UCEC | Gefitinib | EAG | 1.2385e-02 | -0.3413 |  |
chr19:37391306-37392700:+ | UCS | Bosutinib | EER | 1.4704e-02 | -0.4090 |  |
ENSG00000189164.13,ZNF527 | UCS | CI.1040 | EAG | 8.4844e-03 | -0.4381 |  |